Home LiteratureArticle Details
PMID: 16547752 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization.

Medical microbiology and immunology ·Vol. 195 ·No. 3 ·2006-09-00 ·Pages 165-72

Wolk T, Schreiber M

Abstract

Here we report that N-glycans within the V1/V2 variable regions of the NL4-3 gp120 glycoprotein are indispensable to maintain viral functionality and are masking neutralizing epitopes. Fifteen variants of HIV-1 isolate NL4-3 with mutations of the six N-glycosylation sites g2-g7 within the V1 (g2-g4) and V2 loop (g5-g7) of gp120 were analyzed for viral infectivity and their sensitivity to neutralization. Presence of the N-glycans g4, g5, g6 and g7 was an important prerequisite to maintain viral infectivity, since virus mutants lacking these N-glycans were highly deficient in virus entry. Lack of g4 or g7 correlated to a reduction of infectivity to less than 3% of the infectivity observed for NL4-3 wild type. In contrast, mutants lacking N-glycans g2 and g3 showed a 50% increase in infectivity compared to NL4-3. Mutants lacking g2, g3, g5 and g6 with an infectivity of more than 10% of the NL4-3 wt virus were tested for neutralization and showed a high sensitivity against human serum antibody from HIV-1 infected individuals.

MeSH Terms
HIV Antibodies/immunology HIV Envelope Protein gp120/chemistry,physiology HIV Infections/immunology HIV-1/immunology,pathogenicity HeLa Cells Humans Neutralization Tests Polysaccharides/physiology
Chemicals
HIV Antibodies HIV Envelope Protein gp120 Polysaccharides
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Wolk Tobias
Bernhard Nocht Institute for Tropical Medicine, Bernhard Nocht Str. 74, 20359 Hamburg, Germany.
Schreiber Michael
References (30)
30 references, click to expand
  1. Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS.
    Cell. 1986 Jun 6;45(5):637-48 PMID: 2423250
  2. A sensitive radioimmunoprecipitation assay for human immunodeficiency virus (HIV).
    J Immunol Methods. 1988 Sep 13;112(2):235-41 PMID: 3418129
  3. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein.
    J Virol. 1997 Dec;71(12):9808-12 PMID: 9371651
  4. Antibody neutralization and escape by HIV-1.
    Nature. 2003 Mar 20;422(6929):307-12 PMID: 12646921
  5. Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein.
    J Virol. 1998 Jul;72(7):5399-407 PMID: 9620994
  6. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
    J Virol. 2000 Aug;74(15):6769-76 PMID: 10888615
  7. Immunogenicity of full length and truncated forms of the human immunodeficiency virus type I envelope glycoprotein.
    Immunol Lett. 1996 Jun;51(1-2):101-5 PMID: 8811352
  8. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.
    Nature. 1984 Dec 20-1985 Jan 2;312(5996):763-7 PMID: 6096719
  9. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer.
    Virology. 1996 Apr 1;218(1):134-40 PMID: 8615015
  10. A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope.
    J Virol. 2002 Mar;76(5):2075-86 PMID: 11836385
  11. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.
    J Virol. 2001 Sep;75(17):8340-7 PMID: 11483779
  12. Identification of a major co-receptor for primary isolates of HIV-1.
    Nature. 1996 Jun 20;381(6584):661-6 PMID: 8649511
  13. Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.
    AIDS Res Hum Retroviruses. 2001 Jul 20;17(11):1067-76 PMID: 11485624
  14. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.
    J Virol. 2006 Jan;80(2):750-8 PMID: 16378977
  15. Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
    J Virol. 1999 Jul;73(7):5294-300 PMID: 10364275
  16. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization.
    Virology. 1994 Mar;199(2):431-8 PMID: 8122371
  17. Syndecans and HIV-1 pathogenesis.
    Microbes Infect. 2004 May;6(6):617-22 PMID: 15158197
  18. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.
    J Biol Chem. 1990 Jun 25;265(18):10373-82 PMID: 2355006
  19. Syndecan captures, protects, and transmits HIV to T lymphocytes.
    Immunity. 2003 Jan;18(1):27-39 PMID: 12530973
  20. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops.
    J Virol. 2001 Apr;75(7):3435-43 PMID: 11238869
  21. Structure of a V3-containing HIV-1 gp120 core.
    Science. 2005 Nov 11;310(5750):1025-8 PMID: 16284180
  22. Loss of N-linked glycans in the V3-loop region of gp120 is correlated to an enhanced infectivity of HIV-1.
    Glycobiology. 2001 Jan;11(1):11-9 PMID: 11181557
  23. Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4.
    Arch Virol. 1994;139(3-4):253-61 PMID: 7832633
  24. The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors.
    J Virol. 2000 Dec;74(23):11008-16 PMID: 11069996
  25. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
    Science. 1996 May 10;272(5263):872-7 PMID: 8629022
  26. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.
    Virology. 2003 Sep 1;313(2):387-400 PMID: 12954207
  27. The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.
    J Virol. 2005 Jul;79(14):9069-80 PMID: 15994801
  28. A role for carbohydrates in immune evasion in AIDS.
    Nat Med. 1998 Jun;4(6):679-84 PMID: 9623976
  29. The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization.
    Virology. 2002 Dec 5;304(1):70-80 PMID: 12490404
  30. Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120.
    Vaccine. 1998 Nov;16(19):1803-11 PMID: 9795384
Article Info
Journal
Medical microbiology and immunology
Abbr.
Med Microbiol Immunol
ISSN
0300-8584
DOI
10.1007/s00430-006-0016-z
Published
2006-09-00
Epub
2006-00-18
Pages
165-72
Language
English
Region
Germany
NLM ID
0314524
Subset
IM
External Links
PubMed source DOI: 10.1007/s00430-006-0016-z View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2